tradingkey.logo

Penumbra Inc

PEN
316.050USD
+0.700+0.22%
Close 12/19, 16:00ETQuotes delayed by 15 min
12.37BMarket Cap
74.75P/E TTM

Penumbra Inc

316.050
+0.700+0.22%
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison

TradingKey Stock Score of Penumbra Inc

Currency: USD Updated: 2025-12-19

Key Insights

Penumbra Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 19/208 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 313.05.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Penumbra Inc's Score

Industry at a Glance

Industry Ranking
19 / 208
Overall Ranking
82 / 4582
Industry
Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Analyst Rating

Based on 20 analysts
Buy
Current Rating
313.053
Target Price
+6.18%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Penumbra Inc Highlights

StrengthsRisks
Penumbra, Inc. is a thrombectomy company, which is focused on developing technologies for challenging medical conditions, such as ischemic stroke, venous thromboembolism, such as pulmonary embolism, and acute limb ischemia. The Company's broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe. It focuses on developing, manufacturing and marketing novel products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. Some of the conditions it focuses on are Pulmonary Embolism, Deep Vein Thrombosis, Acute Limb Ischemia, Ischemic Stroke, Acute Coronary Syndrome, and Clot associated with Arteriovenous Graft or Fistula. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 41.02% year-on-year.
Undervalued
The company’s latest PE is 74.72, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 37.12M shares, decreasing 7.80% quarter-over-quarter.
Held by Ken Fisher
Star Investor Ken Fisher holds 5.95K shares of this stock.

Financial Health

Currency: USD Updated: 2025-12-19

The current financial score of Penumbra Inc is 8.92, ranking 23/208 in the Healthcare Equipment & Supplies industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 354.69M, representing a year-over-year increase of 17.82%, while its net profit experienced a year-over-year increase of 55.28%.

Score

Industry at a Glance

Previous score
8.92
Change
0

Financials

10.00

Key Metrics

Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.

Quality of Earnings

8.35

Operational Efficiency

9.27

Growth Potential

9.45

Shareholder Returns

7.53

Penumbra Inc's Company Valuation

Currency: USD Updated: 2025-12-19

The current valuation score of Penumbra Inc is 3.84, ranking 205/208 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is 74.72, which is 2592.02% below the recent high of 2011.41 and 7128.90% above the recent low of -5251.80.

Score

Industry at a Glance

Previous score
3.84
Change
0

Valuation Dimensions

P/E
P/B
P/S
P/CF
Industry Ranking 19/208
Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2025-12-19

The current earnings forecast score of Penumbra Inc is 8.40, ranking 38/208 in the Healthcare Equipment & Supplies industry. The average price target for Penumbra Inc is 320.00, with a high of 355.00 and a low of 266.00.

Score

Industry at a Glance

Previous score
8.40
Change
0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 20 analysts
Buy
Current Rating
313.053
Target Price
+6.18%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

112
Total
6
Median
9
Average
Company name
Ratings
Analysts
Penumbra Inc
PEN
20
Medtronic PLC
MDT
35
Stryker Corp
SYK
32
Abbott Laboratories
ABT
31
Dexcom Inc
DXCM
31
Zimmer Biomet Holdings Inc
ZBH
30
1
2
3
...
23

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-12-19

The current price momentum score of Penumbra Inc is 9.32, ranking 12/208 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 330.70 and the support level at 290.39, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
9.36
Change
-0.04

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(1)
Neutral(2)
Buy(2)
Indicators
Value
Direction
MACD(12,26,9)
1.020
Buy
RSI(14)
68.364
Neutral
STOCH(KDJ)(9,3,3)
84.836
Overbought
ATR(14)
9.223
High Vlolatility
CCI(14)
89.361
Neutral
Williams %R
11.698
Overbought
TRIX(12,20)
0.577
Sell
StochRSI(14)
100.000
Buy
Moving Average
Sell(0)
Neutral(0)
Buy(6)
Indicators
Value
Direction
MA5
311.552
Buy
MA10
306.622
Buy
MA20
300.055
Buy
MA50
273.651
Buy
MA100
265.961
Buy
MA200
265.611
Buy

Institutional Confidence

Currency: USD Updated: 2025-12-19

The current institutional shareholding score of Penumbra Inc is 10.00, ranking 1/208 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 94.79%, representing a quarter-over-quarter decrease of 0.97%. The largest institutional shareholder is The Vanguard, holding a total of 3.83M shares, representing 9.77% of shares outstanding, with 3.19% increase in holdings.

Score

Industry at a Glance

Previous score
10.00
Change
0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name
Shares Held
Chg %
Fidelity Management & Research Company LLC
5.04M
+1.90%
The Vanguard Group, Inc.
Star Investors
3.85M
+5.05%
BlackRock Institutional Trust Company, N.A.
3.61M
+2.23%
T. Rowe Price Associates, Inc.
Star Investors
1.34M
+13.99%
State Street Investment Management (US)
1.17M
-2.25%
Elsesser (Adam)
1.02M
+1.21%
Baillie Gifford & Co.
Star Investors
922.13K
+33.84%
RTW Investments L.P.
863.55K
+0.09%
1
2

Risk Assessment

Currency: USD Updated: 2025-12-19

The current risk assessment score of Penumbra Inc is 7.08, ranking 45/208 in the Healthcare Equipment & Supplies industry. The company's beta value is 0.70. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

Score

Industry at a Glance

Previous score
7.08
Change
0
Beta vs S&P 500 index
0.70
VaR
+3.84%
240-Day Maximum Drawdown
+25.75%
240-Day Volatility
+43.90%

Return

Best Daily Return
60 days
+17.32%
120 days
+17.32%
5 years
+17.32%
Worst Daily Return
60 days
-5.04%
120 days
-5.26%
5 years
-10.03%
Sharpe Ratio
60 days
+2.16
120 days
+1.22
5 years
+0.28

Risk Assessment

Maximum Drawdown
240 days
+25.75%
3 years
+52.44%
5 years
+62.56%
Return-to-Drawdown Ratio
240 days
+1.29
3 years
+0.12
5 years
+0.04
Skewness
240 days
+2.24
3 years
+1.08
5 years
+0.83

Volatility

Realised Volatility
240 days
+43.90%
5 years
+43.26%
Standardised True Range
240 days
+2.81%
5 years
+2.67%
Downside Risk-Adjusted Return
120 days
+284.48%
240 days
+284.48%
Maximum Daily Upside Volatility
60 days
+43.80%
Maximum Daily Downside Volatility
60 days
+39.22%

Liquidity

Average Turnover Rate
60 days
+1.19%
120 days
+1.28%
5 years
--
Turnover Deviation
20 days
+2.27%
60 days
+8.96%
120 days
+16.98%

Peer Comparison

Healthcare Equipment & Supplies
Penumbra Inc
Penumbra Inc
PEN
8.06 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Edwards Lifesciences Corp
Edwards Lifesciences Corp
EW
8.61 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
LivaNova PLC
LivaNova PLC
LIVN
8.59 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Artivion Inc
Artivion Inc
AORT
8.59 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Lantheus Holdings Inc
Lantheus Holdings Inc
LNTH
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Tactile Systems Technology Inc
Tactile Systems Technology Inc
TCMD
8.43 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more

FAQs

How does TradingKey generate the Stock Score of Penumbra Inc?

The TradingKey Stock Score provides a comprehensive assessment of Penumbra Inc based on 34 indicators derived from over 100 underlying data points.
These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Penumbra Inc’s performance and outlook.

How do we generate the financial health score of Penumbra Inc?

To generate the financial health score of Penumbra Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns.
By integrating these comprehensive data, the financial health score not only reflects Penumbra Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Penumbra Inc.

How do we generate the company valuation score of Penumbra Inc?

To generate the company valuation score of Penumbra Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Penumbra Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value.
By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Penumbra Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Penumbra Inc.

How do we generate the earnings forecast score of Penumbra Inc?

To calculate the earnings forecast score of Penumbra Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:
Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.
Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.
By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.
Comparing these indicators against peers provides context for the stock’s performance and helps anchor more realistic expectations.
These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Penumbra Inc’s future.

How do we generate the price momentum score of Penumbra Inc?

When generating the price momentum score for Penumbra Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.
Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.
This comprehensive approach can reflect market sentiment and enable rational forecasts of Penumbra Inc’s prices. A higher score indicates a more stable short-term price trend for Penumbra Inc.

How do we generate the institutional confidence score of Penumbra Inc?

To generate the institutional confidence score of Penumbra Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Penumbra Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Penumbra Inc.

How do we generate the risk management score of Penumbra Inc?

To assess the risk management score of Penumbra Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.
The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.
These indicators together provide a multi-dimensional understanding of Penumbra Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Penumbra Inc.
KeyAI